Salute e Benessere

Roche receives CE mark for Contivue, its Port Delivery Platform containing…

Susvimo is under review with the EMA and once approved will be the first continuous delivery treatment for nAMD, affecting 1,7 million in the European Union 1 New seven-year data from the LADDER study show Contivue with Susvimo provides good visual outcomes with stable retinal anatomy over the longer term 2With up to two refills per year, Contivue with Susvimo provides reliable, long-term vision outcomes and is approved in the US for nAMD, diabetic macular edema (DME) and...
Nasdaq GlobeNewswire
04/09/2025

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally…

Press ReleaseNicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approvalGlaukos extends NCX 1728 research agreement Future strategic options under consideration including collaborations or business combinationsQ&A for shareholders...
Nasdaq GlobeNewswire
04/09/2025

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints…

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitisAmlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at Week 24, with efficacy progressively increasing throughout the treatment period Study results reinforce the potential of amlitelimab as the first and only...
Nasdaq GlobeNewswire
04/09/2025

Kuros Biosciences announces changes in the Board of Directors

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences announces changes in the Board of DirectorsSchlieren (Zurich), Switzerland, September 4, 2025– Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, announces that Albert Arp has decided to resign from the Board of Directors with immediate effect for personal and professional reasons.Oliver Walker was appointed as Chair of the Audit and Risk...
Nasdaq GlobeNewswire
04/09/2025

Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business…

Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates Compelling kidney function data and meta-analysis from two Phase 2 studies, VIVIAD and VIVA-MIND, presented in oral presentation at ERA 2025 Expanded IP portfolio including novel composition of matter patent for varoglutamstat granted after accelerated review in the U.S.; patent term to provide exclusivity through 2044 with subsequent opportunity for patent term extensionPre-clinical data showing...
Nasdaq GlobeNewswire
04/09/2025

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints…

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitisAmlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at Week 24, with efficacy progressively increasing throughout the treatment period Study results reinforce the potential of amlitelimab as the first and only...
Nasdaq GlobeNewswire
04/09/2025

BioLab Holdings, Inc. Announces Strategic Investment in AI Diagnostic Technology

cureVision, a Germany-based health tech startup, empowers clinicians to conduct fast, contact-free wound assessments, delivering comprehensive insights in less than two minutes. Certified under the European Medical Device Regulation (MDR), the intuitive system streamlines measurement, analysis, and documentation—helping healthcare professionals to track healing progress while reducing manual workload. With its expertise in advanced optical imaging solutions, the company follows its vision to…
PR Newswire
04/09/2025

Amorepacific Debuts at IFA 2025, Unveils New Beauty Device

Making its global debut at IFA, ONFACE is designed to deliver consistent, even light across the face through 3,770 ultra-thin micro surface-emitting LEDs. With its single-panel LED design and flexible, lightweight materials, the mask fits closely with facial contours for maximum effectiveness. ONFACE's ex vivo test results confirmed that elastin in the skin's deeper layers increased by up to 1,690%[1], while also demonstrating comprehensive improvements in skin condition, including visibly…
PR Newswire
04/09/2025

Myelofibrosis Market is Going to Grow at a CAGR of 9% in the Next Ten Years…

Myelofibrosis Market Summary Myelofibrosis Market Summary Discover which myelofibrosis therapies are expected to grab the largest market share @Myelofibrosis Market Report Key Factors Driving the Growth of the Myelofibrosis Market Novel Therapies Drive Myelofibrosis Treatment Advancements Currently, four JAK inhibitors have been approved by the US FDA for the treatment of myelofibrosis, including JAKAFI (ruxolitinib), INREBIC (fedratinib), VONJO (pacritinib), and...
PR Newswire
03/09/2025

DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global…

DBV Technologies to Participate in the H.C. Wainwright 27 thAnnual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27 thAnnual Global Investment Conference on Tuesday, September 9, 2025, at 11:30am ET, in New York, NY.A live webcast of...
Nasdaq GlobeNewswire
03/09/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 08/31/2025100,325,22989,428,230 For further information on Cellectis, please contact: Media contacts:Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76...
Nasdaq GlobeNewswire
03/09/2025

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care Sleep Institute, a global clinical insights initiative dedicated to advancing the science and understanding of sleep health.Sleep Institute partners with clinicians, researchers, policymakers, and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions, and elevate sleep as a global...
Nasdaq GlobeNewswire
03/09/2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…

Attachment Notification of managers' transaction - Arshad Khanani - September 2025 RSU vest
Nasdaq GlobeNewswire
03/09/2025

BioArctic's founders intend to divest minor part of their shareholding

For further information, please contact: Oskar Bosson, Vice President Communications and Investor RelationsE-mail: [email protected]: +46 70 410 71 80 For further information, please contact: Oskar Bosson, Vice President Communications and Investor Relations E-mail : [email protected]: +46 70 410 71 80 About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the...
PR Newswire
03/09/2025

VALNEVA Declaration of shares and voting rights: August 31, 2025

VALNEVADeclaration of shares and voting rightsAugust 31, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: September 3, 2025 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...
Nasdaq GlobeNewswire
03/09/2025

Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and…

Idorsia will host a live investor Q&A webcast and conference call following the publication of the OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for difficult-to-control hypertension.Date: Monday, September 8, 2025 Time: 16:00 CEST / 15:00 BST / 10:00 EDT The call will start with a short presentation by...
Nasdaq GlobeNewswire
03/09/2025

Ophthalmic Imaging Market worth US$3.84 billion by 2030 with 6.3% CAGR |…

Browse in-depth TOC on "Ophthalmic Imaging Market"411 - Tables57 - Figures343 - Pages Browse in-depth TOC on "Ophthalmic Imaging Market" 411 - Tables 57 - Figures 343 - Pages By product,OCT systems hold the largest market share in the ophthalmic imaging market due to their non-invasive, high-resolution imaging capabilities, which are essential for diagnosing retinal and optic nerve disorders. Widely used for conditions like glaucoma and macular degeneration, OCT systems…
PR Newswire
03/09/2025

GMP Cell Therapy Consumables Market to Reach USD 114.4 Million by 2035, with…

GMP consumables such as culture media, cryopreservation products, single-use bioreactors, and filtration systems are increasingly essential for ensuring product quality, sterility, and regulatory compliance. They support scalable cell expansion, precision manufacturing, and safe clinical outcomes, enabling the broader adoption of cell-based therapies. GMP consumables such as culture media, cryopreservation products, single-use bioreactors, and filtration systems are increasingly essential for...
PR Newswire
03/09/2025

Swine Influenza Vaccines Market Projected to Reach USD 750 Billion by 2033…

The market's trajectory is supported by increasing awareness of disease prevention in livestock, investments in veterinary healthcare, and a shift toward advanced vaccination solutions. Rising demand across both developed and emerging markets is enhancing overall market potential. The market's trajectory is supported by increasing awareness of disease prevention in livestock, investments in veterinary healthcare, and a shift toward advanced vaccination solutions. Rising demand across both...
PR Newswire
03/09/2025

Ophthalmic Devices Market Surges to USD 100.2 Billion by 2033, Propelled by 6.4%…

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=829524 Download PDF Brochure:https://www.verifiedmarketreports.com/download-sample/?rid=829524 Browse in-depth TOCon Ophthalmic Devices Market 202 - Pages 126 – Tables 37 – Figures Scope of The Report Global Ophthalmic Devices Market Overview Ophthalmic Devices Market: Trends and Opportunities What are the most actionable market drivers in ophthalmic devices right...
PR Newswire
03/09/2025

Rotavirus Vaccine Market Is Projected to Reach USD 3.5 Billion by 2033 Driven by…

This expansion is supported by rising vaccination coverage, favorable healthcare policies, and increased investments in pediatric healthcare solutions. With growing demand across both developed and emerging economies, the market is poised for significant advancements, offering substantial opportunities for manufacturers and healthcare providers worldwide. This expansion is supported by rising vaccination coverage, favorable healthcare policies, and increased investments in pediatric healthcare…
PR Newswire
03/09/2025

Laza Medical Achieves First-in-Human Use of Real-Time AI Heart Model for…

Laza's software constructs a patient-specific, 3D heart model in real time using ultrasound data alone. Validating this guidance software is a key step towards first-in-human testing of Laza's complete intelligent robotic imaging system. Laza's software constructs a patient-specific, 3D heart model in real time using ultrasound data alone. Validating this guidance software is a key step towards first-in-human testing of Laza's complete intelligent robotic imaging system. "As a cardiac...
PR Newswire
03/09/2025

Point of Care Molecular Diagnostics Market worth US$7.09 billion by 2030 with…

Browse in-depth TOC on 'Point-of-Care Molecular Diagnostics Market' Browse in-depth TOC on 'Point-of-Care Molecular Diagnostics Market' 355 - Tables 55 - Figures 327 - Pages By technology,the point-of-care molecular diagnostics market, by technology, is segmented into RT-PCR, INAAT, and other technologies. RT-PCR held the largest share of the market in 2024. Its extensive clinical utility, high sensitivity, and quick turnaround time have driven its widespread adoption across...
PR Newswire
03/09/2025

BVI Unveils Virtuoso® – A Novel Dual-Function Surgical Platform for Cataract and…

BVI announces Virtuoso®, its first dual-function phaco-vitrectomy system designed to deliver advanced control, efficiency, and versatility for both cataract and vitreoretinal surgery.European debut planned for 2025 Global ophthalmic congresses in Europe (Euretina and ESCRS). WALTHAM, Mass., Sept.03, 2025(GLOBE NEWSWIRE) -- BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the European market unveiling...
Nasdaq GlobeNewswire
03/09/2025
Altri  Comunicati